STSurendra Kumar Trigun

Surendra Kumar Trigun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Surendra Kumar Trigun has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Natural products as therapeutic interventions for inflammation-mediated cancer

    by Srabaita Roy, Ranjit Shaw, Akanksha Pandey, Surendra Kumar Trigun

    Inflammation serves as the body’s immune response mechanism against noxious irritants, ranging from removing factors causing injury to regenerating damaged tissue. Chronic inflammation, in particular, has emerged as a crucial contributor to both the development of cancer and its spread through a variety of mechanisms. This phenomenon is referred to as inflammation-induced tumorigenesis. Differing from other forms of inflammation that typically precede tumor formation, ‘cancer-elicited inflammation (CEI)’ is induced following the initiation of a tumor. Beyond the cell-autonomous effects observed in cancer cells, the activation of several oncogenes, including KRAS and MYC, coupled with the rendering of tumor suppressors, for instance, TP53 inactive, triggers programs at the transcription level that culminate in the formation of a tumor-encouraging microenvironment. This is accomplished by the overproduction of chemokines and pro-inflammatory cytokines, immune cell recruitment, and the initiation of angiogenesis. Although it is critical to comprehend the mechanisms by which inflammation aids in the development of cancer, the impact that tumors themselves have on the immune system must be considered because these effects have significant repercussions for the therapy and prevention of cancer. This comprehensive review primarily centers on various inflammatory pathways that have been influenced by cancer and have, in turn, influenced cancer progression. Additionally, we delve deeply into the intricate mechanisms through which specific natural products exert regulatory control over the complex molecular foundations that drive their robust anti-inflammatory and anti-cancer effects. Graphical Abstract


  • Modulation of brain energy metabolism in hepatic encephalopathy: impact of glucose metabolic dysfunction

    by Shambhu Kumar Prasad, Arup Acharjee, Vishal Vikram Singh, Surendra Kumar Trigun, Papia Acharjee

    Cerebral function is linked to a high level of metabolic activity and relies on glucose as its primary energy source. Glucose aids in the maintenance of physiological brain activities; as a result, a disruption in metabolism has a significant impact on brain function, launching a chain of events that leads to neuronal death. This metabolic insufficiency has been observed in a variety of brain diseases and neuroexcitotoxicity disorders, including hepatic encephalopathy. It is a significant neurological complication that develops in people with liver disease, ranging from asymptomatic abnormalities to coma. Hyperammonemia is the main neurotoxic villain in the development of hepatic encephalopathy and induces a wide range of complications in the brain. The neurotoxic effects of ammonia on brain function are thought to be mediated by impaired glucose metabolism. Accordingly, in this review, we provide an understanding of deranged brain energy metabolism, emphasizing the role of glucose metabolic dysfunction in the pathogenesis of hepatic encephalopathy. We also highlighted the differential metabolic profiles of brain cells and the status of metabolic cooperation between them. The major metabolic pathways that have been explored are glycolysis, glycogen metabolism, lactate metabolism, the pentose phosphate pathway, and the Krebs cycle. Furthermore, the lack of efficacy in current hepatic encephalopathy treatment methods highlights the need to investigate potential therapeutic targets for hepatic encephalopathy, with regulating deficient bioenergetics being a viable alternative in this case. This review also demonstrates the importance of the development of glucose metabolism-focused disease diagnostics and treatments, which are now being pursued for many ailments.


  • Restoration of hippocampal adult neurogenesis by CDRI‐08 (Bacopa monnieri extract) relates with the recovery of BDNF–TrkB levels in male rats with moderate grade hepatic encephalopathy

    by Debasmit Mallick, Arup Acharjee, Papia Acharjee, Surendra Kumar Trigun

    Modulation of in vivo adult neurogenesis (AN) is an evolving concept in managing neurodegenerative diseases. CDRI‐08, a bacoside‐enriched fraction of Bacopa monnieri, has been demonstrated for its neuroprotective actions, but its effect on AN remains unexplored. This article describes the status of AN by monitoring neuronal stem cells (NSCs) proliferation, differentiation/maturation markers and BDNF–TrkB levels (NSCs signalling players) vs. the level of neurodegeneration and their modulations by CDRI‐08 in the hippocampal dentate gyrus (DG) of male rats with moderate grade hepatic encephalopathy (MoHE). For NSC proliferation, 10 mg/kg b.w. 5‐bromo‐2′‐deoxyuridine (BrdU) was administered i.p. during the last 3 days, and for the NSC differentiation study, it was given during the first 3 days to the control, the MoHE (developed by 100 mg/kg b.w. of thioacetamide i.p. up to 10 days) and to the MoHE male rats co‐treated with 350 mg/kg b.w. CDRI‐08. Compared with the control rats, the hippocampus DG region of MoHE rats showed significant decreases in the number of Nestin+/BrdU+ and SOX2+/BrdU+ (proliferating) and DCX+/BrdU+ and NeuN+/BrdU+ (differentiating) NSCs. This was consistent with a similar decline in BDNF+/TrkB+ NSCs. However, all these NSC marker positive cells were observed to be recovered to their control levels, with a concordant restoration of total cell numbers in the DG of the CDRI‐08‐treated MoHE rats. The findings suggest that the restoration of hippocampal AN by CDRI‐08 is consistent with the recovery of BDNF–TrkB‐expressing NSCs in the MoHE rat model of neurodegeneration.


  • The restoration of hippocampal nerve de‐myelination by methylcobalamin relates with the enzymatic regulation of homocysteine level in a rat model of moderate grade hepatic encephalopathy

    by Anima Roy, Surendra Kumar Trigun

    This article describes how methylcobalamin (MeCbl) restores nerve myelination in a moderate‐ grade hepatic encephalopathy (MoHE) model of ammonia neurotoxicity. The comparative profiles of myelin basic protein (MBP), homocysteine (Hcy) and methionine synthase (MS: a MeCbl‐ dependent enzyme) activity versus nerve myelination status were studied in the hippocampus of the control, the MoHE (developed by administering 100 mg/kg bw thioacetamide i.p. for 10 days) and the MoHE rats treated with MeCbl (500 µg/kg BW i.p.) for 7 days. Compared to those of control rats, the hippocampal CA1 and CA3 regions of the MoHE rats showed significantly lower myelinated areas and MBP immunostaining. This coincided with the deranged myelin layering in TEM images, decreased MBP protein and its transcript levels in hippocampus of MoHE rats. However, all these parameters recovered to normal levels after MeCbl treatment. MeCbl is a cofactor of MS that catalyzes the conversion of Hcy to methionine as a feeder step of methylation reactions. We observed significantly increased serum and hippocampal Hcy levels in MoHE rats, however, these levels were restored to control values with a concordant activation of MS due to MeCbl treatment. A significant recovery in neurobehavioral impairments in the MoHE rats due to MeCbl treatment was also observed. These findings suggest that MoHE pathogenesis is associated with deranged nerve myelination in the hippocampus and that MeCbl treatment is able to restore it mainly by activating MS, a MeCbl‐dependent Hcy‐metabolizing enzyme.


  • Open Access

    Probenecid, a Pannexin1 inhibitor, restores deranged NMDA receptor and nNOS profiles in cerebellum of minimal hepatic encephalopathy rats

    by Papia Acharjee, Arup Acharjee, Shambhu Kumar Prasad, Vishal Vikram Singh, Debasmit Mallick, Surendra K Trigun

    Modulating Pannexin1 (Panx1), an ATP exit channel, in brain cells as a therapeutic option for neurological disorders, is an evolving concept. Our previous report on concordant increase in Panx1 vs neuronal nitric oxide synthase (nNOS) in cerebellum of the minimal hepatic encephalopathy (MHE) rats led us to explore whether Panx1 could be modulated to ameliorate the neurochemical aberrations related to MHE pathogenesis. This article describes the effect of Panx1 inhibition by probenecid (PB) on the relative profile of NMDA receptor (NMDAR)-nNOS axis and the level of degenerating cerebellar Purkinje cells vs recovery in the motor function deficit in a neurobehaviorily characterized MHE rats developed by administering 50 mg/kg bw thioacetamide intraperitoneally for 14 days. As compared to the control group rats, cerebellum of the MHE rats showed concordant increases in the level and activities of Panx1 and nNOS with a concomitant decline in the ratio of NMDAR subunit 2A/2B coinciding with atrophy of the purkinje cells. Moreover, all these parameters were observed to be recovered back to their control levels due to the treatment with a Panx1 inhibitor, Probenecid (PB), to the MHE rats. Such a recovery in the neurochemical parameters were found to be consistent with the restoration of Purkinje cell population and the MHE associated impaired rota-rod performance tests. The findings underscore PB-mediated Panx1 inhibition as a promising therapeutic avenue for ameliorating the MHE pathogenesis related neurochemical aberration and motor coordination deficits.


  • Fisetin induces apoptosis in colorectal cancer cells by suppressing autophagy and down‐regulating nuclear factor erythroid 2‐related factor 2 (Nrf2)

    by Akanksha Pandey, Surendra Kumar Trigun

    Modulation of autophagy is evolving as a relevant strategy in cancer pathogenesis and therapeutic intervention and hence, needs to be examined as a target for the promising anticancer agents. Fisetin, a dietary flavanol, is emerging as a potent anticancer agent, however, its tumour‐specific pharmacological targets remain largely unexplored. This article describes correlative profiles of autophagy and apoptotic markers versus nuclear factor erythroid 2‐related factor 2 (Nrf2) and reactive oxygen species (ROS) in the colorectal cancer (CRC) cell line SW‐480. As compared to the untreated cells, significantly less number of fluorescent detected autophagic vacuoles (AVOs) in the fisetin‐treated cells coincided with a similar decline of the autophagy flux markers, Beclin 1 and microtubule‐associated protein‐1 light chain‐3 and accumulation of p62 in those cells. The significantly increased number of annexin‐V/propidium iodide (+/+) positive and acridine orange/ethidium bromide‐stained apoptotic cells coincided with the enhanced signals for the cleaved caspase 3 and nuclear PARP‐1 in those fisetin‐treated cells. This was consistent with the collapse of mitochondrial membrane potential and release of cytochrome c. The fisetin‐treated cells showed increased ROS level and a significant decline in nuclear Nrf2 immunosignal versus recovery in nuclear Nrf2 due to the treatment with curcumin and resveratrol (Nrf2 activators) and thus, suggesting a role of Nrf2 suppression in fisetin‐mediated apoptosis in SW‐480 cells. The effect of chloroquine, an autophagy inhibitor, resulted into declined number of AVOs and enhanced apoptosis, similar to that of the fisetin effect. Also, regaining of AVOs number and reduced apoptosis of CRC cells due to the treatment with rapamycin, an autophagy inducer, could be observed. These loss and gain of functions experiments thus suggested a correlation between fisetin‐mediated autophagy suppression and apoptotic induction in a colorectal cell line.


  • Hippocampus mitochondrial MnSOD activation by a SIRT3 activator, honokiol, correlates with its deacetylation and upregulation of FoxO3a and PGC1α in a rat model of ammonia neurotoxicity

    by Anamika, Anima Roy, Surendra K. Trigun

    We have recently reported that honokiol (HKL), by activating mitochondrial SIRT3, normalizes reactive oxygen species level and mitochondrial integrity in hippocampus of the moderate grade hepatic encephalopathy (MoHE) rat model of ammonia neurotoxicity. To delineate the mechanism by which HKL does so, the present study describes activity versus level of the deacetylated mitochondrial Mn‐superoxide dismutase (MnSOD) and expression of MnSOD versus levels of its main transcription regulators, FoxO3a and PGC1α, in the hippocampus of the MoHE rats. MoHE in rat was developed by administration of 100 mg/kg bw thioacetamide i.p. for 10 days. The study parameters were compared between the control, the MoHE rats and the MoHE rats treated with HKL (10 mg/Kg b.w.) for 7 days. As compared to control, the hippocampus mitochondria from MoHE rats showed a significantly declined activity of MnSOD vs enhanced lipid peroxidation coinciding with the increased level of its acetylated form. The HKL treatment could, however, normalize all these parameters in those MoHE rats. Also, a significantly reduced expression of MnSOD in the hippocampus of the MoHE rats coincided with a similar decline in transcript level of Foxo3a and Pgc1α. This was consistent with the reduced level of immuno‐stained Foxo3a and Pgc1α proteins in hippocampus DG, CA1 and CA3 regions of those MoHE rats. However, all these factors were observed to be restored back to their normal levels due to the treatment with HKL. As HKL is a specific activator of mitochondrial SIRT3, these findings suggest involvement of Sirt3 activation led deacetylation of MnSOD and upregulation of its transcription activators, FoxO3a and PGC1α, in restoring mitochondrial MnSOD level in the hippocampus of the MoHE rat model of ammonia neurotoxicity.


  • Resveratrol modulates NMDAR-nNOS axis in the cerebellum of a neuroexcitotoxic model of Hepatic encephalopathy

    by Archita Khanna, Surendra Kumar Trigun

    Resveratrol (RSV), a natural plant derived phytoalexin, is known to exhibits its biological activity by activating Sirt1 which confers neuroprotection under a variety of neurological complications like ischemia, Alzheimer’s disease etc. Hepatic Encephalopathy (HE) is a disorder of mental activity, neuromuscular function and consciousness that occurs as a result of liver dysfunction, involving Nmethyl-D-aspartate receptor (NMDAR) over activation in brain cells, causing excitotoxicity. Therapeutic modulation of this glutamate receptor, therefore,needs to be investigated to define cerebral mechanism based management of HE. This article evaluates the effect of RSV as herbal supplement in modulation of NMDAR-nNOS (neuronal nitric oxide synthase) axis in the cerebellum of rats with moderate grade HE (MoHE) induced by administration of 100 mg/kg b.w. of thioacetamide i.p. for 10 days. In another set, the MoHE rats were co-treated with RSV 10mg/Kg bw i.p from 8th day of TAA treatment up to 14 days.As compared to the NR2A dominated NMDAR composition observed in the cerebellum of the control rats, the MoHE rats showedenhanced NR2B dominated NMDAR expression. The level of nNOS and NO are considered as a biochemical assay for the NMDAR activity. Both, nNOS expression and NO levels, as compared to the control rats, were found to be enhanced in the cerebellum of the MoHE rats. However, all these parameters were observed to regain their normal levels in the cerebellum of the MoHE rats treated with RSV. The findings suggest that resveratrol could act as a neuroprotectant against MoHE pathogenesis by modulating NMDARnNOS axis in cerebellum.

  • Cilostamide, a phosphodiesterase 3A inhibitor, sustains meiotic arrest of rat oocytes by modulating cyclic adenosine monophosphate level and the key regulators of maturation promoting factor

    by Anumegha Gupta, Surendra Kumar Trigun

    Cilostamide, a phosphodiesterase 3A (Pde3A) inhibitor, is known to increase intraoocyte cyclic adenosine monophosphate (cAMP) level which is involved in sustaining meiotic arrest of the oocytes. To explore the mechanisms involved in the cilostamide‐mediated meiotic arrest of the oocytes, the present study describes the effects of cilostamide on cAMP level and related factors involved in maturation of the oocytes at its different meiotic stages; diplotene, metaphase I (MI) and metaphase II (MII). The oocytes from these three stages were collected from rat ovary and incubated with 10 µM cilostamide for 3 h in CO2 incubator. The levels of cAMP, cyclic guanosine monophosphate (cGMP) and the key players of maintaining meiotic arrest during oocyte maturation; Emi2, Apc, Cyclin B1, and Cdk1, were analyzed in diplotene, MI and MII stages. Pde3A was found to be expressed at all three stages but with the lowest level in MI oocyte. As compared to the control sets, the cAMP concentration was found to be highest in MII whereas cGMP was highest in the diplotene stage of cilostamide‐treated group. The treated group showed declined reactive oxygen species level as compared with the control counterparts. Relatively increased levels of the Emi2, Cyclin B1, and phosphorylated thr161 of Cdk1 versus declined levels of phosphorylated thr14/tyr15 of Cdk1 in diplotene and MII stage oocytes are known to be involved in maintaining meiotic arrest and all these factors were found to undergo similar pattern of change due to the treatment with cilostamide. The findings thus suggest that cilostamide treatment promotes meiotic arrest by Pde3A inhibition led increase of both cAMP and cGMP level vis‐a‐vis modulation of the related regulatory factors such as Emi2, CyclinB1, and phosphorylated status of Cdk1 in diplotene and MII stage oocytes. Such a mechanism of meiotic arrest could allow the oocyte to prepare itself for meiotic maturation and thereby to improve oocyte quality.


  • Open Access

    Honokiol, a SIRT3 activator, activates hippocampus mitochondrial MnSOD by deacetylating the enzyme and upregulating FoxO3a-PGC1α axis in a rat model of ammonia neurotoxicity

    by Anamika Anamika, Surendra Kumar Kumar Trigun

    We have recently reported that honokiol (HKL), by activating mitochondrial SIRT3, restored ROS led deranged mitochondrial integrity associated with the pathogenesis of ammonia neurotoxicity induced moderate grade hepatic encephalopathy (MoHE). To delineate mechanism by which HKL does so, the present study describes activity vs acetylation level of the mitochondrial MnSOD and its expression vs levels of its main transcription regulators; FOXO3a, PGC1α, in the hippocampus of the MoHE rat model of ammonia neurotoxicity, developed by administration of 100 mg/kg bw of thioacetamide i.p. for 10 days, and in the MoHE rats treated with HKL (10 mg/Kg b.w.) for 7 days. As compared to the control, the hippocampus mitochondria from MoHE rats showed a significantly declined activity of MnSOD coinciding with the increased level of its acetylated form which however, could be restored back due the HKL treatment. Also, a significantly reduced expression of MnSOD in the hippocampus of those MoHE rats coincided with a similar decline in transcript level of FOXO3a and PGC1α. This was consistent with the reduced immunoreactivity of FOXO3a and PGC1α in the hippocampus DG, CA1 and CA3 regions of the MoHE rats. However, all these factors were observed to be restored back to their normal levels in the hippocampus of the MoHE rats treated with HKL. As HKL activates mitochondrial SIRT3, these findings suggest involvement of Sirt3 activation led deacetylation of MnSOD and upregulation of its transcription activators; FOXO3a and PGC1α in activating mitochondrial MnSOD in the hippocampus of the MoHE rat model of ammonia neurotoxicity.